Nachrichten zur Eli Lilly & Co. Aktie

Why Major Pharmaceutical Stocks Tumbled on Tuesday

Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administrations…

Eli Lilly says company has no affiliation with Hims & Hers

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims hers…

‘Don’t Fall for the Hype,’ Says Top Analyst about HIMS’ Decision to Sell Zepbound

Shares of Hims Hers Health ($HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded…

Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day,…

Why Hims & Hers Health Stock Soared Tuesday

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up…

Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it…

Hims & Hers to sell Eli Lillys Zepbound on its platform

Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs…

BofA says Hims & Hers Zepbound sales will be ‘immaterial’

BofA keeps an Underperform rating on Hims Hers with a $22 price target after the company indicated it is…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health NYSE:HIMS said on Monday it plans to sell Eli Lillys NYSE:LLY diabetes and weight-loss…

Eli Lilly obesity drug on Hims & Hers platform (HIMS:NYSE)

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lillys (LLY) weight loss therapy tirzepatide & generic…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…

Hims & Hers to sell Lillys Zepbound on its telehealth platform

Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…

Hims & Hers to Sell Lillys Zepbound on Its Telehealth Platform

(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on…

Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.…

Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro…

Statement: Lilly has no affiliation with hims & hers | Eli Lilly and Company

The Investor Relations website contains information about Eli Lilly and Companys business for stockholders, potential investors, and financial analysts.…

Where Will Eli Lilly Be in 1 Year?

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.…

Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading…

94 % geringeres Herzerkrankungsrisiko! Lepodisiran von Eli Lilly senkt Risikofaktor deutlich laut seiner Phase-2-Ergebnisse!

Das Pharmaunternehmen Eli Lilly and Company (LLY) hat am Sonntag, den 30. März 2025, einen Bericht über seine Ergebnisse der…

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

…

1 Growth Stock With Major Catalysts on the Way to Buy and Hold

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its…

WDH/EU-Behörde: Kein grünes Licht für Alzheimer-Medikament

(Wirkstoffname berichtigt: 1. Absatz, 2. Satz: Donanemab (statt Donemab).) AMSTERDAM (dpa-AFX) - Die…

EU-Behörde: Kein grünes Licht für Alzheimer-Medikament

AMSTERDAM (dpa-AFX) - Die EU-Arzneimittelbehörde EMA hat kein grünes Licht für die Zulassung eines Alzheimer-Medikaments von…

Why Novo Nordisk Stock Dipped on Thursday

Novo Nordisks (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like…

1 Growth Stock Down 40% to Buy and Hold Forever

This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past…

Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025

Mounjaro and Zepbound are Eli Lillys largest sources of growth, but there is much more to the company.…

Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 @themotleyfool #stocks $LLY $BIIB $ESAI.Y

Mounjaro and Zepbound are Eli Lillys largest sources of growth, but there is much more to the company.…

Eli Lilly (LLY) Stock Sinks As Market Gains: Heres Why

Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.…

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical…

The market comeback continues — plus, a key catalyst is on the horizon for Eli Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly will soon release key data on its weight loss pill. Heres why it could be a game-changer

The trial results are critical, as it brings Eli Lillys pill one step closer to becoming a new, needle-free alternative…

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped

Theres a price war brewing in GLP-1 weight loss drugs, and now its going global.…

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped @themotleyfool #stocks $NVO $LLY $HIMS

Theres a price war brewing in GLP-1 weight loss drugs, and now its going global.…

Motley Fool 2025 March Market Cap Showdown Championship

It all comes down to this...the final round of the Motley Fool Rule Breaker Investing March Market Cap Showdown! Defending…

Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?

Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining…

Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

Its hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug…

Zepbound copycats remain online despite FDA ban

Copycat versions of Eli Lillys diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. Theyre…

J&J touts $55B in planned US investments over 4 years, including 3 new manufacturing sites

Johnson & Johnson says it will s | Johnson & Johnson will invest $55 billion in the U.S. over the…

Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India By Investing.com

Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India…

Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market By Reuters

Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market…

Lillys weight-loss drug launch in India to energize rivals eyeing mega market

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20…

Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval

Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from countrys drug regulator, it…

Eli Lilly (LLY) Stock Moves -0.27%: What You Should Know

Eli Lilly (LLY) concluded the recent trading session at $822.51, signifying a -0.27% move from its prior days close.…

Trump Tariffs and the Nasdaq Correction Have Been No Match for These Stock Market Sectors

The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024. The Nasdaq…

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Are you reluctant to invest in stocks right now? Thats understandable. Fear, uncertainty, and doubt have become the norm in…

An Ozempic successor falls short, Eli Lillys GLP-1 pill, and senators grill RFK: Pharma news roundup

Plus, Eli Lillys CEO got a pay raise, and Viking Therapeutics gets closer to bringing its Ozempic competitor to market…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading…

Why Hims & Hers Health Stock Just Popped

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it would…

Is Eli Lilly Stock a Buy?

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and its an element you…

Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth…